GRI Bio (GRI) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
10 Dec, 2025Management team and governance
President and CEO is W. Marc Hertz, Ph.D.; other key executives include Leanne Kelly (CFO), David Szekeres (Chairperson), David Baker, Roelof Rongen, and Camilla V. Simpson (Directors).
Employment agreements are in place for key executives, including Marc Hertz, Leanne M. Kelly, and Vipin Kumar Chaturvedi, dated February 20, 2023.
Amended and Restated Non-Employee Director Compensation Program and indemnification agreements are established.
Underwriters and syndicate
H.C. Wainwright & Co., LLC serves as exclusive underwriter, agent, or advisor for offerings, with compensation including a 7% cash fee on gross proceeds (3% for ATM takedowns, 3.5% for insider participation).
Wainwright receives warrants to purchase 7% of shares placed in each offering, with terms matching investor warrants but an exercise price at 125% of the offering price.
Expense allowances include a 1% management fee, $25,000 for non-accountable expenses, and up to $100,000 for legal fees in public offerings.
The engagement agreement with Wainwright was amended multiple times, most recently on December 5, 2025, extending the term by 12 months if an offering is consummated and removing the right of first refusal.
Offering details and pricing
The registration statement is for a proposed public offering of securities, to commence as soon as practicable after effectiveness.
Multiple forms of warrants and equity instruments are included as part of the offering structure.
The offering is on a reasonable best efforts basis, with no guarantee of successful capital raise.
Latest events from GRI Bio
- Lead candidate improved lung function and fibrosis biomarkers in IPF, with strong safety data.GRI
Corporate presentation16 Mar 2026 - Positive phase 2A IPF results and IND plans for lupus program signal strong pipeline momentum.GRI
Corporate Connect Webinar Series11 Feb 2026 - Strong cash position and positive clinical data support continued pipeline advancement.GRI
Q4 20254 Feb 2026 - Biopharma seeks up to $250M for immune therapies, advancing IPF and lupus programs amid high risk.GRI
Registration Filing30 Jan 2026 - Reverse stock split and adjournment proposals approved; results to be filed on Form 8-K.GRI
EGM 202615 Jan 2026 - Shareholders to vote on a reverse stock split to help maintain Nasdaq listing and flexibility.GRI
Proxy Filing29 Dec 2025 - Stockholders to vote on a reverse stock split to support Nasdaq compliance at a virtual meeting.GRI
Proxy Filing19 Dec 2025 - Registering 1.58M shares for resale from warrants, with proceeds only if warrants are exercised.GRI
Registration Filing16 Dec 2025 - Biopharma seeks $8.6M to advance IPF and autoimmune drug pipeline amid financial and Nasdaq risks.GRI
Registration Filing8 Dec 2025